Pneumatosis intestinalis induced by osimertinib in a patient with lung adenocarcinoma harbouring epidermal growth factor receptor gene mutation with simultaneously detected exon 19 deletion and T790 M point mutation: a case report

[1]  Ying Cheng,et al.  Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer , 2018 .

[2]  M. Ahn,et al.  Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.

[3]  K. Shimizu,et al.  Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report , 2016, World Journal of Surgical Oncology.

[4]  Jean Mosser,et al.  Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) , 2016, The Lancet.

[5]  S. Lam,et al.  Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma. , 2015, Oncology letters.

[6]  T. Yamanaka,et al.  Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non-small-cell lung cancer. , 2014, Lung cancer.

[7]  山本 愛,et al.  A case of lung cancer complicating pneumatosis intestinalis during beyond progressive disease therapy , 2014 .

[8]  Y. Ichinose,et al.  LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Y. Yang,et al.  A systematic analysis of pneumatosis cystoids intestinalis. , 2013, World journal of gastroenterology.

[10]  Y. Janjigian,et al.  Distinguishing benign and life-threatening pneumatosis intestinalis in patients with cancer by CT imaging features. , 2013, AJR. American journal of roentgenology.

[11]  A. Shinagare,et al.  Pneumatosis intestinalis and bowel perforation associated with molecular targeted therapy: an emerging problem and the role of radiologists in its management. , 2012, AJR. American journal of roentgenology.

[12]  O. Lee,et al.  Pneumatosis intestinalis and portal venous gas secondary to Gefitinib therapy for lung adenocarcinoma , 2012, BMC Cancer.

[13]  Hiromasa Harada,et al.  [Pneumatosis cystoides intestinalis in a patient with lung cancer]. , 2010, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society.

[14]  W. Mutschler,et al.  Natural history, clinical pattern, and surgical considerations of pneumatosis intestinalis , 2009, European journal of medical research.

[15]  E. Paulson,et al.  Pneumatosis intestinalis in the adult: benign to life-threatening causes. , 2007, AJR. American journal of roentgenology.

[16]  Y. Tabata,et al.  Therapeutic effects of rectal administration of basic fibroblast growth factor on experimental murine colitis. , 2005, Gastroenterology.

[17]  A. Davidoff,et al.  Pneumatosis Intestinalis: Surgical Management and Clinical Outcome , 1990, Annals of surgery.

[18]  T. Ishiwata,et al.  A Case of Pneumatosis Cystoides Intestinalis During Systemic Chemotherapy for Small-cell Lung Cancer , 2013 .

[19]  K. Kunimasa,et al.  Pneumatosis cystoides intestinalis after gefitinib therapy for pulmonary adenocarcinoma. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  M. Tachibana,et al.  Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib , 2012 .

[21]  S. S. St. Peter,et al.  The spectrum of pneumatosis intestinalis. , 2003, Archives of surgery.